These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 22840210)

  • 21. Histopathologic features, immunophenotyping, clonality, and eubacterial fluorescence in situ hybridization in cats with lymphocytic cholangitis/cholangiohepatitis.
    Warren A; Center S; McDonough S; Chiotti R; Goldstein R; Meseck E; Jacobsen M; Rowland P; Simpson K
    Vet Pathol; 2011 May; 48(3):627-41. PubMed ID: 21097715
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group.
    van Hoogstraten HJ; Vleggaar FP; Boland GJ; van Steenbergen W; Griffioen P; Hop WC; van Hattum J; van Berge Henegouwen GP; Schalm SW; van Buuren HR
    Am J Gastroenterol; 2000 Aug; 95(8):2015-22. PubMed ID: 10950051
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Autoimmune cholangitis or primary biliary cirrhosis without antimitochondrial antibodies?].
    Saló J; Caballería L; Bruguera M; Parés A; Rodés J
    Gastroenterol Hepatol; 1997 Jan; 20(1):5-10. PubMed ID: 9072202
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment.
    Stiehl A; Rudolph G; Sauer P; Theilmann L
    J Hepatol; 1995 Sep; 23(3):283-9. PubMed ID: 8550992
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stratified medicine and primary biliary cholangitis.
    Mells GF; Jones DE
    Lancet Gastroenterol Hepatol; 2017 May; 2(5):319-321. PubMed ID: 28397694
    [No Abstract]   [Full Text] [Related]  

  • 26. Sclerosing cholangitis with granulocytic epithelial lesion: a benign form of sclerosing cholangiopathy.
    Zen Y; Grammatikopoulos T; Heneghan MA; Vergani D; Mieli-Vergani G; Portmann BC
    Am J Surg Pathol; 2012 Oct; 36(10):1555-61. PubMed ID: 22982898
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy.
    Färkkilä M; Rautiainen H; Kärkkäinen P; Karvonen AL; Nurmi H; Niemelä O
    Liver Int; 2008 Jul; 28(6):787-97. PubMed ID: 18397236
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Use of ursodeoxycholic acid combined with silymarin in the treatment of chronic ethyl-toxic hepatopathy].
    Bettini R; Gorini M
    Clin Ter; 2002; 153(5):305-7. PubMed ID: 12510413
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Autoimmune cholangitis presented as fever of unknown origin.
    Petrogiannopoulos C; Papamichael K; Karachalios G; Karachaliou I; Kostakos N; Barbati K; Zacharof A
    Chemotherapy; 2006; 52(6):282-4. PubMed ID: 17008778
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of ursodeoxycholic acid and endoscopic sphincterotomy in long-term stenting for common bile duct stones.
    Nishizawa T; Suzuki H; Takahashi M; Kaneko H; Suzuki M; Hibi T
    J Gastroenterol Hepatol; 2013 Jan; 28(1):63-7. PubMed ID: 23094786
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute seronegative autoimmune hepatitis.
    Ozaslan E; Samsar U; Erden E
    Hepatogastroenterology; 2010; 57(98):334-5. PubMed ID: 20583438
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Prevention of clogging of biliary stents by administration of levofloxacin and ursodeoxycholic acid].
    Sciumè C; Geraci G; Pisello F; Facella T; Li Volsi F; Modica G
    Chir Ital; 2004; 56(6):831-7. PubMed ID: 15771038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic approaches for hepatobiliary disorders with ursodeoxycholic acid and bile-acid derivatives.
    Serfaty L; Poupon R
    Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S1. PubMed ID: 23141887
    [No Abstract]   [Full Text] [Related]  

  • 34. Ultrasonographic findings of feline cholangitis.
    Marolf AJ; Leach L; Gibbons DS; Bachand A; Twedt D
    J Am Anim Hosp Assoc; 2012; 48(1):36-42. PubMed ID: 22186719
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemoprevention of colorectal cancer with ursodeoxycholic acid: cons.
    Carey EJ; Lindor KD
    Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S61-4. PubMed ID: 23141896
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prolonged cholestasis due to hepatitis A virus infection.
    Kumar P; Bhatia V
    Indian Pediatr; 2011 Jun; 48(6):485-6. PubMed ID: 21743116
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ursodeoxycholic acid improves insulin sensitivity and hepatic steatosis by inducing the excretion of hepatic lipids in high-fat diet-fed KK-Ay mice.
    Tsuchida T; Shiraishi M; Ohta T; Sakai K; Ishii S
    Metabolism; 2012 Jul; 61(7):944-53. PubMed ID: 22154323
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ofloxacin and ursodeoxycholic acid versus ursodeoxycholic acid alone to prevent occlusion of biliary stents: a prospective, randomized trial.
    Halm U; Schiefke ; Fleig WE; Mössner J; Keim V
    Endoscopy; 2001 Jun; 33(6):491-4. PubMed ID: 11437041
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic use of cytoprotective agents in canine and feline hepatobiliary disease.
    Webster CR; Cooper J
    Vet Clin North Am Small Anim Pract; 2009 May; 39(3):631-52. PubMed ID: 19524797
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Primary biliary cirrhosis].
    Corpechot C
    Gastroenterol Clin Biol; 2003 Mar; 27(3 Pt 1):320-4. PubMed ID: 12700520
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.